GNAO1功能协同突变在儿童急性淋巴细胞白血病中的作用
研究通过对一对出生后相继发病、ETV6-RUNX1融合阳性但不一致的儿童ALL同卵双胞胎进行全外显子测序,发现GNAO1 R209C突变为新的ALL风险位点。GNAO1错义突变在ALL患者中反复出现并与E/R融合相关,R209C突变增强GTP酶活性、促进细胞增殖和恶性转化,与E/R融合协同激活PI3K/Akt/mTOR信号通路促进白血病发生。
要点
- GNAO1 R209C是新的儿童ALL风险位点,与ETV6-RUNX1融合协同致白血病。
- GNAO1错义突变在ALL中反复出现,且与E/R融合相关。
- GNAO1 R209C与E/R融合通过激活PI3K/Akt/mTOR信号通路协同促进白血病发生。
核心结论
- GNAO1突变与ETV6-RUNX1融合在人类白血病中功能协同,提示GNAO1可作为治疗靶点。
研究设计与样本
- 对一对出生后相继发生ETV6-RUNX1融合阳性儿童ALL的同卵双胞胎进行全外显子测序。
- 在ALL患者中分析GNAO1错义突变的反复出现及其与E/R融合的关联。
- 通过体外实验研究GNAO1 R209C突变对GTP酶活性、细胞增殖和恶性转化的影响。
主要发现
- GNAO1 R209C突变被鉴定为新的ALL风险位点。
- GNAO1错义突变在ALL患者中反复出现并与E/R融合相关。
- GNAO1 R209C异位表达增加GTP酶活性并促进细胞增殖和细胞恶性转化。
- GNAO1 R209C与E/R融合协同通过激活PI3K/Akt/mTOR信号通路促进白血病发生。
- 激活的mTORC1磷酸化p300乙酰转移酶,后者乙酰化E/R并增强E/R对GNAO1 R209C的转录活性。
临床怎么用
- GNAO1突变可作为ALL潜在治疗靶点,尤其在与E/R融合共存的患者中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Leukemogenesis is characterized by chromosomal rearrangements with additional molecular disruptions, yet the cooperative mechanisms are still unclear. Using whole-exome sequencing of a pair of monozygotic twins who were discordant for childhood acute lymphoblastic leukemia (ALL) with ETV6-RUNX1 (E/R) gene fusion successively after birth, we identified the R209C mutation of G protein subunit α o1 (GNAO1) as a new ALL risk loci. Moreover, GNAO1 missense mutations are recurrent in ALL patients and are associated with E/R fusion. Ectopic expression of the GNAO1 R209C mutant increased its GTPase activity and promoted cell proliferation and cell neoplastic transformation. Combined with the E/R fusion, the GNAO1 R209C mutation promoted leukemogenesis through activating PI3K/Akt/mTOR signaling. Reciprocally, activated mTORC1 phosphorylated p300 acetyltransferase, which acetylated E/R and thereby enhanced the E/R transcriptional activity of GNAO1 R209C. Thus, our study provides clinical evidence of the functional cooperation of GNAO1 mutations and E/R fusion, suggesting GNAO1 as a therapeutic target in human leukemia.
引用
- Song L, Yu B, Yang Y, et al. Identification of functional cooperative mutations of GNAO1 in human acute lymphoblastic leukemia. Blood. 2021. PMID: 32898863. doi:10.1182/blood.2020005622
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。